FDA issues EUA for Eli Lilly’ monoclonal antibody COVID-19 treatment

by on

FDA issues EUA for Eli Lilly’ monoclonal antibody COVID-19 treatment
tjordan_drupal
Nov 10, 2020

The Food and Drug Administration Nov. 10 issued an emergency use authorization for Eli Lilly and Company’s monoclonal antibody therapy, bamlanivimab.

The EUA authorizes the product’s use, but only in outpatient settings; additionally, it sets forth the type of patients eligible to receive the treatment, the drug’s storage requirements and a brief overview of how distribution will work.

Operation Warp Speed will begin to distribute nearly 80,000 vials of this therapy today, with most hospitals anticipated to receive their allocation tomorrow or Thursday. 

Headline

FDA issues EUA for Eli Lilly’ monoclonal antibody COVID-19 treatment
tjordan_drupal
Nov 10, 2020

The Food and Drug Administration Nov. 10 issued an emergency use authorization for Eli Lilly and Company’s monoclonal antibody therapy, bamlanivimab.

The EUA authorizes the product’s use, but only in outpatient settings; additionally, it sets forth the type of patients eligible to receive the treatment, the drug’s storage requirements and a brief overview of how distribution will work.

Operation Warp Speed will begin to distribute nearly 80,000 vials of this therapy today, with most hospitals anticipated to receive their allocation tomorrow or Thursday. 

Novel Coronavirus (COVID-19)
COVID-19: CDC, FDA and CMS Guidance

Headline

VA:F [1.9.7_1111]
Rating: 0.0/10 (0 votes cast)
VA:F [1.9.7_1111]
Rating: 0 (from 0 votes)

Leave a Comment

Previous post:

Next post: